Literature DB >> 15635931

The return to work experiences of colorectal cancer survivors.

Kathleen M Sanchez1, Jean L Richardson, Hyacinth R C Mason.   

Abstract

During the past 15 years, the number of colorectal cancer survivors has risen dramatically. While it is unclear how many colorectal cancer survivors were employed at the time of diagnosis, it is reasonable to expect a significant proportion of these survivors were temporarily displaced from the work force. This article describes the return to work experiences of 250 colorectal cancer survivors. The majority (80%) of the survivors were employed at diagnosis and 89% returned to work. Of those who returned to work, 81% sustained employment 5 years postdiagnosis. Results indicate survivors were successful in their attempt to return to work and sustain employment. However, 34% of survivors delayed their return beyond 2 months postdiagnosis. After controlling for ethnicity, education, and disease severity, the reason for delay was related to chemotherapy treatment. Prospective studies of colorectal cancer survivors to document barriers to work return can guide interventions and occupational services to keep survivors healthy and in the workplace.

Entities:  

Mesh:

Year:  2004        PMID: 15635931

Source DB:  PubMed          Journal:  AAOHN J        ISSN: 0891-0162


  25 in total

1.  Insights in work rehabilitation after minimally invasive esophagectomy.

Authors:  Melissa Geeraerts; Luis Carlos Silva Corten; Marc van Det; Misha Luyer; Grard Nieuwenhuijzen; Marloes Vermeer; Jelle Ruurda; Richard van Hillegersberg; Ewout Kouwenhoven
Journal:  Surg Endosc       Date:  2019-01-29       Impact factor: 4.584

2.  A controlled cohort study of long-term income in colorectal cancer patients.

Authors:  Beate Hauglann; Jūratė Saltytė Benth; Sophie D Fosså; Kjell M Tveit; Alv A Dahl
Journal:  Support Care Cancer       Date:  2014-05-13       Impact factor: 3.603

3.  Unemployment risk 2 years and 4 years following gastric cancer diagnosis: a population-based study.

Authors:  Yakir Rottenberg; Jeremy M Jacobs; Navah Z Ratzon; Albert Grinshpun; Miri Cohen; Beatrice Uziely; Angela G E M de Boer
Journal:  J Cancer Surviv       Date:  2016-08-31       Impact factor: 4.442

4.  Understanding the symptom experience of patients with gastrointestinal cancers in the first year following diagnosis: findings from a qualitative longitudinal study.

Authors:  J Ellis; S G Brearley; O Craven; A Molassiotis
Journal:  J Gastrointest Cancer       Date:  2013-03

5.  Returning to work after treatment for haematological cancer: findings from Australia.

Authors:  Pam D McGrath; Barbara Hartigan; Hamish Holewa; Maryanne Skarparis
Journal:  Support Care Cancer       Date:  2011-10-28       Impact factor: 3.603

6.  Employment and retirement status of older cancer survivors compared to non-cancer siblings.

Authors:  Mary E Sesto; Mahpara Faatin; Sijian Wang; Amye J Tevaarwerk; Douglas A Wiegmann
Journal:  Work       Date:  2013

7.  One-third of patients fail to return to work 1 year after surgery for colorectal cancer.

Authors:  A Bhalla; J P Williams; N G Hurst; W J Speake; G M Tierney; S Tou; J N Lund
Journal:  Tech Coloproctol       Date:  2014-11-08       Impact factor: 3.781

8.  Risk for unemployment at 10 years following cancer diagnosis among very long-term survivors: a population based study.

Authors:  Yakir Rottenberg; Angela G E M de Boer
Journal:  J Cancer Surviv       Date:  2020-02-14       Impact factor: 4.442

9.  Employment outcomes among survivors of common cancers: the Symptom Outcomes and Practice Patterns (SOAPP) study.

Authors:  A J Tevaarwerk; J W Lee; M E Sesto; K A Buhr; C S Cleeland; J Manola; L I Wagner; V T S Chang; M J Fisch
Journal:  J Cancer Surviv       Date:  2013-02-02       Impact factor: 4.442

Review 10.  Genetic testing for Lynch syndrome in the first year of colorectal cancer: a review of the psychological impact.

Authors:  Karin M Landsbergen; Judith B Prins; Han G Brunner; Floris W Kraaimaat; Nicoline Hoogerbrugge
Journal:  Fam Cancer       Date:  2009-03-28       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.